NextCell publishes its Interim Report 3 2022/2023

July 27, 2023

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 3 for the period March 1, 2023 – May 31, 2023 The report is available on the company’s website:
https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.

Third quarter (2023-03-01 until 2023-05-31)

Operating income amounted to 4,190 (1,636) TSEK, of which Cellaviva counted for 3,039 (1,613) TSEK.
Operating result amounted to -10,915 (-9,307) TSEK.
Earnings per share* amounted to -0.32 (-0.27) SEK.
Cash and bank amounted to 63,230 (107,054) TSEK.
Solidity** amounted to 88.1 (92.7) %

First nine months (2022-09-01 until 2023-05-31)

Operating income amounted to 9,937 (4,823) TSEK of which Cellaviva counted for 7,284 (4,230) TSEK.
Operating result amounted to -31,242 (-25,991) TSEK.
Earnings per share* amounted to -0.91 (-0.76) SEK.

*Earnings per share: Profit for the period divided by average number of shares. Average number of shares for the third quarter 2022/2023: 34,379,523 (34,379,523) shares. Number of shares in NextCell as of May 31, 2023: 34,379,523 (34,379,523) shares.
**Solidity: Own capital's share of the sheet total.

Significant events in the third quarter

NextCell announced at the end of March that the results of the clinical phase I/II study in type 1 diabetes had been accepted for publication in the peer-reviewed journal Diabetologia, the official journal of the European Association for the Study of Diabetes
The company announced late April that the FDA has approved a product of multiplied stem cells from umbilical cord blood. It is a breakthrough that could lead to increased interest in saving stem cells for private use, where Cellaviva is the market leader in Scandinavia.

Significant events after the reporting period

NextCell announced at the beginning of July that the clinical trial ProTrans 19+SE (also called Protrans V) would start recruiting patients in the high dose group, which is the last dose group. Three patients treated with medium dose of ProTrans have been clinically evaluated and the data has been reviewed by the Data Safety Monitoring Board, which now allows continued treatment with high-dose ProTrans for severe pneumonia caused by COVID-19, Influenza, Human Metapneumovirus and RSV.

This disclosure contains information that NextCell Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 27-07-2023 07:30 CET.

For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 55 95
E-mail: info@nextcellpharma.com
Website:www.nextcellpharma.com

Linkedin: https://www.linkedin.com/NextCell-Pharma
Twitter: https://twitter.com/NextCellPharma

For more information about Cellaviva, please contact
Sofie Falk Jansson, Head of Cellaviva
Tel: +46 8 735 20 10
E-mail: info@cellaviva.se
Website:www.cellaviva.se

Facebook: https://www.facebook.com/cellavivasverige
Instagram: https://www,instagram.com/cellaviva

Certified Adviser
FNCA Sweden AB is assigned as Certified Adviser, info@fnca.se.

About NextCell Pharma AB
NextCell is a cell therapy company in clinical phase II. The company has developed a proprietary and patented platform technology to produce mesenchymal stromal cells adapted for allogeneic treatment of various autoimmune and immunological diseases. The drug candidate ProTrans is now being tested for the treatment of type-1 diabetes as well as respiratory complications caused by Sars-CoV-2 infection. The focus is to take ProTrans to market approval for type-1 diabetes via a phase III study. ProTrans is evaluated in two clinical COVID-19 studies, in Sweden and Canada. NextCell is working on completing its own GMP facility for the manufacture of ProTrans. The GMP facility is expected to be ready for manufacturing smaller quantities of ProTrans in 2023. NextCell also owns 8.5% of FamicordTX, a start-up company in CAR-T and oncology, and 100% of Cellaviva, Scandinavia's largest stem cell bank for family savings of stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO).

Download attachment Read full press release on Cision (external link)

2017-07-31

NextCell Pharma updates on its current situation in its first quarterly report

NextCell Pharma AB (”NEXTCL”, “NextCell”) today, released its first quarterly report (April-June) since its introduction on Aktietorget. Following the issue in July, and after payment of study drug the Company has approximately SEK 20 million in cash, while the "burn rate" for the reporting period (April-June) was 3.5 MSEK (listing on Aktietorget occurred after the closing of this quarterly report). During the reporting period NextCell Pharma has recruited Leo Groenewegen, who took up the position of CFO. Besides his duties as CFO, Leo Groenewegen, together with Chairman Anders Essen-Moller,

Read more Read more

2017-07-24

NextCell Pharma AB submits clinical trial application for its drug candidate ProTrans™

NextCell Pharma AB ("NextCell") announced today that a clinical trial application for ProTrans™, a stem cell product developed with NextCell's Proprietary Selection Algorithm, has been submitted to the Medical Products Agency (Läkemedelsverket). The study is planned to evaluate the safety and efficacy of ProTrans™ in adult patients with type 1 diabetes diagnosed within two years. The study sponsor is NextCell and the principal investigator is Professor Per-Ola Carlsson, who works at Uppsala University and the Academic Hospital in Uppsala. The study will be conducted together with Karolinska

Read more Read more

2017-07-19

Disclosure notice: NextCell Pharma AB’s Chairman of the Board acquires additional shares

NextCell Pharma AB (”NextCell”) announces today, on July 19th 2017, that Chairman of the Board, Anders Essen-Möller, has acquired 263.020 shares in the company. Before the acquisition, Essen-Möller held 737.033 shares, equivalent to approximately 8.74 percent of the votes and capital. After the acquisition, Essen-Möller holds 1.000.053 shares, equivalent to approximately 11.76 percent of the votes and capital in NextCell.

Read more Read more

2017-07-13

First day of trading in stem cell company NextCell Pharma AB

NextCell Pharma AB (”NextCell”) announces today that trading with its shares and warrants of series TO 1 will commence today at the AktieTorget stock exchange. The shares will be traded under the name “NEXTCL” with the corresponding ISIN code SE009723125. The warrants will be designated with the name “NEXTCL TO 1” and ISIN code SE009888795. NextCell develops stem cell therapies, where stem cells from donated umbilical cords can treat patients who are not family of the donor. The cells are developed with NextCell's proprietary method and the company's first product, ProTrans™, is intended for

Read more Read more